Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 4, 2021. The filing addresses a strategic evaluation of the Company's reporting structure to reflect its expanded international presence following the June 2021 acquisition of Alliance Healthcare.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses the methodology for reporting segment information. The Company is voluntarily furnishing unaudited revised reportable segment information for each quarter of fiscal 2021 and the fiscal year ended September 30, 2021, in Exhibit 99.1 to align with the new structure.
Material Changes Versus Prior Period
Effective the first quarter of fiscal 2022, the Company re-aligned its reporting structure from its legacy format to two new reportable segments:
- U.S. Healthcare Solutions: Includes the legacy Pharmaceutical Distribution Services (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.
- International Healthcare Solutions: Includes Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.
Notably, Profarma was moved from the legacy Pharmaceutical Distribution Services segment to the new International Healthcare Solutions segment, and Profarma Specialty was moved from "Other" to International Healthcare Solutions.
Guidance, Outlook, and Management Commentary
Management commentary focuses on the operational necessity of the restructuring to better reflect the Company's global footprint. The filing states that results will be reported under this new structure beginning in the first quarter of fiscal 2022. No specific financial guidance, risk factors, or contingencies regarding future performance are detailed in this specific text.
Important Facts for Investor Verification
- Review Exhibit 99.1 for the unaudited revised segment data for fiscal 2021 to understand the historical impact of the restructuring.
- Verify the composition of the new "U.S. Healthcare Solutions" and "International Healthcare Solutions" segments for future comparative analysis.
- Note that the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference in a future filing.